

Open Peer Review on Qeios

Glioma Lysate Vaccine GBM6-AD

National Cancer Institute

Source

National Cancer Institute. <u>Glioma Lysate Vaccine GBM6-AD</u>. NCI Thesaurus. Code C139000.

An allogeneic cell lysate-based vaccine derived from the glioma stem cell line GBM6-AD, which was isolated from the brain tumor of a patient diagnosed with glioblastoma multiforme (GBM), with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration, the glioma lysate vaccine GBM6-AD exposes the immune system to an undefined amount of glioma-associated antigens (GAAs), and stimulates the immune system to mount a specific anti-tumoral, cytotoxic T-lymphocyte (CTL)-mediated response against the GAA-expressing cells, resulting in glioma cell lysis.

Qeios ID: JNT140 · https://doi.org/10.32388/JNT140